Journal
JOURNAL OF SUBSTANCE ABUSE TREATMENT
Volume 44, Issue 5, Pages 473-480Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jsat.2012.10.004
Keywords
Drug courts; Methadone; Buprenorphine; Naltrexone; Medication-assisted treatment
Categories
Funding
- NIAID NIH HHS [5P30AI042853, P30 AI042853] Funding Source: Medline
- NIDA NIH HHS [K24 DA022112, 1R01DA030778, R01 DA030778, R01 DA022122, 1R21DA029201, R01 DA027211, 5R01DA027211, R21 DA029201, 5K24DA22122] Funding Source: Medline
Ask authors/readers for more resources
Drug treatment courts are an increasingly important tool in reducing the census of those incarcerated for nonviolent drug offenses; medication assisted treatment (MAT) is proven to be an effective treatment for opioid addiction. However, little is known about the availability of and barriers to MAT provision for opioid-addicted people under drug court jurisdiction. Using an online survey, we assessed availability, barriers, and need for MAT (especially agonist medication) for opioid addiction in drug courts. Ninety-eight percent reported opioid-addicted participants, and 47% offered agonist medication (56% for all MAT including naltrexone). Barriers included cost and court policy. Responses revealed significant uncertainty, especially among non-MAT providing courts. Political, judicial and administrative opposition appear to affect MAT's inconsistent use and availability in drug court settings. These data suggest that a substantial, targeted educational initiative is needed to increase awareness of the treatment and criminal justice benefits of MAT in the drug courts. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available